Kato Naoto | Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
スポンサーリンク
概要
関連著者
-
Kato Naoto
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Eda Hiroyuki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Kojima Midori
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Ohmi Takashi
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Ohmi Takashi
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
KOJIMA Midori
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
KATO Naoto
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
EDA Hiroyuki
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
Eda Hiroyuki
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Ueno Yoshinobu
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Matsuura Tomomi
Pharmacokinetics Dynamics & Metabolism Global Research & Development Nagoya Laboratories Pfi
-
Moriguchi Yukiko
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Yamamoto Mitsuko
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Suzuki Sachiko
Pharmacokinetics Dynamics & Metabolism Global Research & Development Nagoya Laboratories Pfi
-
HIRANO Daisuke
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
OCHI Takashi
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
NII Aisuke
Drug Safety Research and Development ; Global Research and Development, Nagoya Laboratories, Pfizer
-
SHINJO Katsuhiro
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
UENO Yoshinobu
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
YAMAMOTO Mitsuko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
MORIGUCHI Yukiko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
SHIMOZONO Rieki
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
SUZUKI Sachiko
Pharmacokinetics, Dynamics & Metabolism, Global Research & Development, Nagoya Laboratories, Pfizer
-
MATSUURA Tomomi
Pharmacokinetics, Dynamics & Metabolism, Global Research & Development, Nagoya Laboratories, Pfizer
-
Hirano Daisuke
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Shinjo Katsuhiro
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Nii Aisuke
Drug Safety Research And Development ; Global Research And Development Nagoya Laboratories Pfizer Ja
-
Suzuki Sachiko
関西学院大学 理工学部ナノバイオテクノロジー研究開発センター
-
Shimozono Rieki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Ochi Takashi
Discovery Biology Nagoya Laboratories Pfizer Global Research And Development
-
Nii Aisuke
Drug Safety Research & Development Nagoya Laboratories Pfizer Global Research And Development
-
Eda Hiroyuki
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Shimozono Rieko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Ueno Yoshinobu
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Yamamoto Mitsuko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Ohmi Takashi
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
-
Matsuura Tomomi
Pharmacokinetics, Dynamics & Metabolism, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc., Japan
著作論文
- Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against .ALPHA.-Fas-Induced Liver Injury in a Mouse Model